DelveInsight's "Chemotherapy Induced Nausea and Vomiting - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Chemotherapy Induced Nausea and Vomiting epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.
Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2016-2028
Chemotherapy Induced Nausea and Vomiting Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Chemotherapy Induced Nausea and Vomiting in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Chemotherapy Induced Nausea and Vomiting outlook. It also includes the explanation of changing trends of epidemiology outlining the Chemotherapy Induced Nausea and Vomiting scenario.
Chemotherapy Induced Nausea and Vomiting Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chemotherapy Induced Nausea and Vomiting thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.
Report Scope
• The report covers detailed overview of Chemotherapy Induced Nausea and Vomiting explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Chemotherapy Induced Nausea and Vomiting Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population
Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Chemotherapy Induced Nausea and Vomiting
Key assessments
• Patient Segmentation in Chemotherapy Induced Nausea and Vomiting
• Chemotherapy Induced Nausea and Vomiting Risk & Burden
• Factors driving growth in a specific Chemotherapy Induced Nausea and Vomiting patient population
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chemotherapy Induced Nausea and Vomiting in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chemotherapy Induced Nausea and Vomiting in 7MM – By Countries
5. Epidemiology of Chemotherapy Induced Nausea and Vomiting by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.1.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.1.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.1.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.4.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.4.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.4.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.5.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.5.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.5.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.6.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.6.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.6.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.7.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.7.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.7.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.8.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.8.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.8.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting
5.9.3. Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting *
5.9.4. Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting *
5.9.5. Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting
6. Unmet Needs of the Chemotherapy Induced Nausea and Vomiting
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Table 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in 7MM
Table 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)*
Table 6: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028) *
Table 13: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028) *
Table 14: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028) *
Table 26: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028) *
Figure 14: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Chemotherapy Induced Nausea and Vomiting in Japan (2016-2028)
$3250
$6500
$9750
